Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 10/20 | 0.62 |
| ▸ | EGFR | P00533 | 1/20 | 0.58 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.58 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.55 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.55 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.55 |
| ▸ | PI4KA | P42356 | 1/20 | 0.55 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.55 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.55 |
| ▸ | ALK | Q9UM73 | 5/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.48 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22048959 | 0.80 | MET (0.65) | METEGFRERBB2ERBB4NPC1 | |
| SCHEMBL29757180 | 0.75 | NPC1 (1.00) | NPC1POLBRAB9APIK3CDPIK3CA | |
| SCHEMBL30743 | 0.75 | NPC1 (1.00) | NPC1POLBRAB9APIK3CDPIK3CA | |
| SCHEMBL30468943 | 0.74 | EGFR (0.48) | METEGFRERBB2ERBB4DYRK1A | |
| SCHEMBL30695495 | 0.73 | PIK3CD (0.55) | PIK3CDPIK3CAPIK3CBPI4KAPIK3CG | |
| SCHEMBL22119811 | 0.73 | DPP4 (0.54) | METEGFRERBB2ERBB4PIK3CD | |
| SCHEMBL21876272 | 0.71 | PIK3CD (0.53) | PIK3CDPIK3CAPIK3CBPI4KAPIK3CG | |
| SCHEMBL29369075 | 0.71 | PIK3CD (0.53) | PIK3CDPIK3CAPIK3CBPI4KAPIK3CG | |
| SCHEMBL30142182 | 0.70 | CNR2 (0.44) | METALK | |
| SCHEMBL23048839 | 0.70 | DYRK1A (0.61) | DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240101549-A1 | N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOETHYL)-QUINOLINE-4-CARBOXAMIDES | ASTRAZENECA AB (SE) | 2024-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240101549-A1 | N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOETHYL)-QUINOLINE-4-CARBOXAMIDES | FAP, PREP, CTRL | MET 1203/4885EGFR 1749/4885ERBB2 2283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.